Skip to main content

Table 3 Difference in ΔeGFR and the risk of adverse renal events according to quartile of urinary A-megalin

From: Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study

 

Quartile of urinary A-megalin

P

Q1 (n = 11)

Q2 (n = 12)

Q3 (n = 11)

Q4 (n = 11)

ΔeGFR (mL/min/1.73 m2)

−3.8

±6.7

−15.2

±15.1

−11.9

±18.0

−20.8

±18.5

0.085a

Estimated difference (95% CI) from Q1 (mL/min/1.73 m2)

 Crude

0.00

(reference)

−11.39

(−24.30, 1.51)+

−8.05

(−21.23, 5.14)

−16.95

(−30.13, −3.76)*

0.018b

 Adjusted

0.00

(reference)

−10.00

(−22.29, 2.38)

−4.94

(−17.73, 7.85)

−13.27

(−26.17, −0.37)*

0.064b

Adverse renal events / person-days

2

/ 194

7

/ 146

6

/ 129

9

/ 95

 

Event rate (/10 person days)

0.103

0.479

0.465

0.947

 

Hazard ratio (95% CI)

 Crude

1.00

(reference)

4.25

(0.88, 20.51)+

4.04

(0.81, 20.09)+

7.24

(1.55, 33.96)*

0.008b

 Adjusted

1.00

(reference)

3.80

(0.78, 18.48)+

3.03

(0.60, 15.30)

4.39

(0.91, 21.13)+

0.093b

  1. CI, confidence interval; eGFR, estimated glomerular filtration rate. ΔeGFR, maximum change from the baseline value to the lowest value of eGFR during follow-up. An adverse renal event was defined as an eGFR decline of > 10 mL/min/1.73 m2. Adjusted hazard ratio, adjusted for baseline eGFR. +P < 0.1, *P < 0.05, aP for statistical difference between groups, bP for trend